Ligand-supported homology modeling of the human angiotensin II type 1 (AT1) receptor: Insights into the molecular determinants of telmisartan binding

Proteins: Structure, Function and Genetics

Volumn 65, Issue 4, 2006, Pages 824-842

  Patny, Akshay ^a,b   Desai, Prashant V ^a,b   Avery, Mitchell A ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

AT1 receptor; Docking; Drug design; GPCR; Homology modeling; Losartan; Molecular dynamics; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LIGAND; LOSARTAN; RHODOPSIN; TELMISARTAN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENERGY; HUMAN; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SEQUENCE HOMOLOGY; SIMULATION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS;

AMINO ACID SEQUENCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BINDING SITES; CATTLE; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; RHODOPSIN; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY, PROTEIN;

BOS TAURUS;

EID: 33751086742     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21196     Document Type: Article

References (62)

1. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996;39:625-656.
2. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472.
3. Schmidt B, Schleifer B. Angiotensin II ATI receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003;46:2261-2270.
4. Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 1992;183:1090-1096.
5. Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK, Dzau VJ. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Commun 1992;185:253-259.
6. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993;268:24543-24546.
7. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268:24539-24542.
8. Tsuzuki S, Ichiki T, Nakakubo H, Kitami Y, Guo DF, Shirai H, Inagami T. Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor. Biochem Biophys Res Commun 1994;200:1449-1454.
9. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000;21:90-113.
10. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739-745.
11. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000;28:235-242.
12. Baldwin JM. The probable arrangement of the helices in G protein-coupled receptors. EMBO J 1993;12:1693-1703.
13. Baldwin JM, Schertler GF, Unger VM. An α-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 1997;272:144-164.
14. Ballesteros J, Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr Opin Drug Discov Dev 2001;4:561-574.
15. Filipek S, Teller DC, Palczewski K, Stenkamp R. The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. Annu Rev Biophys Biomol Struct 2003;32:375-397.
16. OliveiraL, Hulsen T, Lutje Hulsik D, Paiva AC, Vriend G. Heavier-than-air flying machines are impossible. FEBS Lett 2004;564:269-273.
17. Bissantz C, Bernard P, Hibert M, Rognan D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins 2003;50:5-25.
18. Hillisch A, Pineda LF, Hilgenfeld R. Utility of homology models in the drug discovery process. Drug Discov Today 2004;9:659-669.
19. Zhang Y, Devries ME, Skolnick J. Structure modeling of all identified G protein-coupled receptors in the human genome. PLoS Comput Biol 2006;2:e13.
20. Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, Zamanakos G, Goddard WA, III. Prediction of structure and function of G protein-coupled receptors. Proc Natl Acad Sci USA 2002;99:12622-12627.
21. Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol 1990;213:899-929.
22. Schertler GF, Villa C, Henderson R. Projection structure of rhodopsin. Nature 1993;362:770-772.
23. Underwood DJ, Strader CD, Rivero R, Patchett AA, Greenlee W, Prendergast K. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol 1994;1:211-221.
24. Joseph MP, Maigret B, Bonnafous JC, Marie J, Scheraga HA. A computer modeling postulated mechanism for angiotensin II receptor activation. J Protein Chem 1995;14:381-398.
25. Yamano Y, Ohyama K, Kikyo M, Sano T, Nakagomi Y, Inoue Y, Nakamura N, Morishima I, Guo DF, Hamakubo T, Tadashi I. Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J Biol Chem 1995;270:14024-14030.
26. Balmforth AJ, Lee AJ, Warburton P, Donnelly D, Ball SG. The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J Biol Chem 1997;272:4245-4251.
27. Bondensgaard K, Ankersen M, Thogersen H, Hansen BS, Wulff BS, Bywater RP. Recognition of privileged structures by G-protein coupled receptors. J Med Chem 2004;47:888-899.
28. Cappelli A, Pericot Mohr Gl G, Gallelli A, Rizzo M, Anzini M, Vomero S, Mennuni L, Ferrari F, Makovec F, Menziani MC, De Benedetti PG, Giorgi G. Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure. J Med Chem 2004;47:2574-2586.
29. Takezako T, Gogonea C, Saad Y, Noda K, Karnik SS. "Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J Biol Chem 2004;279:15248-15257.
30. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA 2002;99:5982-5987.
31. Hoe KL, Saavedra JM. Site-directed mutagenesis of the gerbil and human angiotensin II AT(1) receptors identifies amino acid residues attributable to the binding affinity for the nonpeptidic antagonist losartan. Mol Pharmacol 2002;61:1404-1415.
32. Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneben H, Entzeroth M, van Meel JC, Wienen W, Hauel NH. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem 1993;36:4040-4051.
33. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815.
34. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000;9:1753-1773.
35. Maple JR, Dinur U, Hagler AT. Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. Proc Natl Acad Sci USA 1988;85:5350-5354.
36. Sheik SS, Sundararajan P, Hussain AS, Sekar K. Ramachandran plot on the web. Bioinformatics 2002;18:1548,1549.
37. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003;52:609-623.
38. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748.
39. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995;245:43-53.
40. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001;105:6474-6487.
41. Bairoch A, Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res 2000;28:45-48.
42. Visiers I, Ballesteros JA, Weinstein H. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 2002;343:329-371.
43. Persson B, Argos P. Topology prediction of membrane proteins. Protein Sci 1996;5:363-371.
44. Gutierrez-de-Teran H, Centeno NB, Pastor M, Sanz F. Novel approaches for modeling of the Al adenosine receptor and its agonist binding site. Proteins 2004;54:705-715.
45. Boeckler F, Lanig H, Gmeiner P. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. J Med Chem 2005;48:694-709.
46. Kim SK, Gao ZG, Van Rompaey P, Gross AS, Chen A, Van Calenbergh S, Jacobson KA. Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem 2003;46:4847-4859.
47. Lavecchia A, Cosconati S, Novellino E. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. J Med Chem 2005;48:2480-2492.
48. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comp Phys 1977;23:327-341.
49. Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comp Chem 1996;17:490-519.
50. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 2003;42:2759-2767.
51. Hunyady L, Balla T, Catt KJ. The ligand binding site of the angiotensin AT1 receptor. Trends Pharmacol Sci 1996;17:135-140.
52. Zhang Y, Sham YY, Rajamani R, Gao J, Portoghese PS. Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system. Chembiochem 2005;6:853-859.
53. Tebben A, Kimura SR, Carter PH, Zhao Q, Krystek SR, Jr. Binding site xpansion and induced fit docking for GPCR ligand binding mode prediction: application to the b-adrenergic and chemokine receptors. Abstracts of Papers, Presented at 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006 (2006:COMP-124).
54. Kimura SR, Rajamani R, Langley D. Opening up binding sites of homology models via a balloon potential: a molecular dynamics refinement approach. Abstracts of Papers, Presented at 230th ACS National Meeting, Washington, DC, United States, Aug 28-Sept 1, 2005 (2005:COMP-336).
55. Kimura SR, Krystek S, Jr, Tebben A, Langley DR. Systematic active site refinement of GPCR models through molecular dynamics simulation. Abstracts of Papers, Presented at 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006 (2006:COMP-218).
56. Pepin MC, Yue SY, Roberts E, Wahlestedt C, Walker P. Novel "restoration of function" mutagenesis strategy to identify amino acids of the δ-opioid receptor involved in ligand binding. J Biol Chem 1997;272:9260-9267.
57. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, Kobilka BK. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 1997;272:2587-2590.
58. Pedretti A, Villa M, Pallavicini M, Valoti E, Vistoli G. Construction of human ghrelin receptor (hGHS-R1a) model using a fragmental prediction approach and validation through docking analysis. J Med Chem 2006;49:3077-3085.
59. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A, Karnik SS. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995;270:2284-2289.
60. Chakravarty PK, Naylor EM, Chen A, Chang RS, Chen TB, Faust KA, Lotti VJ, Kivlighn SD, Gable RA, Zingaro GJ, Schorn TW, Schaffer LW, Broten TP, Siegl PKS, Patchett AA, Greenlee WJ. A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist. J Med Chem 1994;37:4068-4072.
61. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol 2004;342:571-583.
62. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004;43:993-1002.